Assessing recent milestones in AAV capsid discovery & development for CNS applications
Cell & Gene Therapy Insights 2023; 9(4), 447–453
DOI: 10.18609/cgti.2023.065
Published: 9 May 2023
Interview
Mathieu Nonnenmacher
The CNS presents a formidable challenge to gene therapy developers, but the rapidly growing sophistication of viral gene delivery systems offer new hope to the field. David McCall, Senior Editor, BioInsights, speaks to (pictured) Voyager Therapeutics’ Mathieu Nonnenmacher, Vice President, Novel Capsid Discovery about his team’s work in discovering and developing novel AAV capsids with enhanced properties including tissue tropism.
